3rd Quarter - Report

TIBER CREEK GROUP for ROIVANT SCIENCES, INC.

Firm
Client
Income
$70,000
Expenses
—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Telecommunications TEC

Issues pertaining to telemedicine and implementation of Special Registration rule. Implementation of SUPPORT for Patients and Communities Act (Public Law No: 115-271).

Contacted: Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

Treatment of diabetes, gene therapies and treatment of Parkinsons disease, telemedicine

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB)

Budget/Appropriations BUD

Treatment of diabetes, gene therapies, treatment of Parkinsons disease, HR 2740 the Labor-HHS Appropriations Bill

LobbyistCovered position, as disclosed
MATTHEW LEFFINGWELL —

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); SENATE

Bills named: H.R. 2740 (116th)

Pharmacy PHA

Treatment of diabetes, gene therapies and treatment of Parkinsons disease

Contacted: HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); SENATE

Foreign entities

Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.

EntityCountryPrincipal place of businessOwnershipContribution declared
ROIVANT SCIENCES LTD. Bermuda Bermuda — —
ROIVANT SCIENCES HOLDINGS LTD. United Kingdom United Kingdom — —

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.